Japan Approves FoundationOne CDx as Companion Diagnostic for Tovorafenib in BRAF-Altered Glioma
核心洞察
Chugai obtained MHLW approval on June 17, 2026 for FoundationOne CDx as a companion diagnostic for tovorafenib in BRAF (搜索) V600 alteration- and BRAF fusion-positive glioma (搜索).
The approval allows the comprehensive genomic profiling test to guide treatment decisions for tovorafenib, an anti-cancer BRAF (搜索) inhibitor marketed in Japan by IPSEN.
Tovorafenib's efficacy and safety in relapsed or progressive low-grade glioma (搜索) were evaluated in the overseas Phase II FIREFLY-1 study.
Chugai Pharmaceutical Co., Ltd. announced that it obtained approval from Japan's Ministry of Health, Labour and Welfare (MHLW) on June 17, 2026 for FoundationOne®CDx Cancer Genomic Profile to be used as a companion diagnostic for Ojemda® Tablets 100 mg and Ojemda Dry Syrup 300 mg (generic name: tovorafenib), an anti-cancer agent and BRAF (搜索) inhibitor. The diagnostic is indicated for BRAF V600 alterations and BRAF fusion gene-positive glioma (搜索).
The approval enables detection of BRAF (搜索) V600 alterations and BRAF fusion genes using FoundationOne CDx to guide the decision to use tovorafenib in this patient population. IPSEN Co., Ltd. (搜索), which holds the Japanese regulatory approval for tovorafenib, received that approval from the MHLW on September 16, 2026.
FIREFLY-1 Trial Supports the Indication
The efficacy and safety of tovorafenib for relapsed or progressive low-grade glioma (搜索) with BRAF (搜索) V600 alterations or BRAF fusion gene-positive status were evaluated in an overseas Phase II clinical study, the FIREFLY-1 study. The companion diagnostic approval is tied to that clinical evidence base, allowing the genomic profile test to inform which patients are eligible for treatment with the BRAF inhibitor.
Expanding Companion Diagnostic Coverage
FoundationOne CDx Cancer Genomic Profile (搜索) has continuously expanded its companion diagnostic capabilities, enabling a single comprehensive genomic profiling test to support treatment decisions for multiple medicines. With the addition of the new companion diagnostic for glioma (搜索), the test now has companion diagnostic capabilities covering 9 cancer types, including solid tumors. Chugai stated that this is expected to further enhance the test's clinical utility.
Personalized Oncology Strategy
Chugai, describing itself as a leading company in oncology, said it is committed to realizing more advanced personalized healthcare in the oncology field and contributing to patients through the wider adoption of comprehensive genomic profiling. The glioma (搜索) companion diagnostic approval represents the latest step in that effort, pairing a molecularly defined patient population with a targeted BRAF (搜索) inhibitor through a single genomic testing platform.